Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novoste Sees More Beta-Cath Placements, Looks To Exploit First Mover Lead

This article was originally published in The Gray Sheet

Executive Summary

Novoste Corp. expects to place 220-280 Beta-Cath brachytherapy systems in top U.S. centers by the end of 2001, an increase from the company's previous guidance of 180-250 placements for the year.
Advertisement

Related Content

Novoste Narrows Focus For Primary Indication In Light Of Beta-Cath Trial
Novoste Narrows Focus For Primary Indication In Light Of Beta-Cath Trial
Advertisement
UsernamePublicRestriction

Register

MT014691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel